Effect of Intravenous Gammaglobulin on Circulating and Platelet-Bound Antibody in Immune Thrombocytopenia

• Published in: Blood Vol. 73; no. 3; pp. 662 - 665
• Main Authors: Barbano, Giancarlo, Saleh, Mansoor N., Mori, P.G., LoBuglio, Albert F., Shaw, Denise R.
• Format: Journal Article
• Language: English
• Published: Washington, DC Elsevier Inc 15.02.1989; The Americain Society of Hematology
• Subjects: Autoantibodies - immunology; Autoimmune Diseases - therapy; Biological and medical sciences; Blood Platelets - immunology; gamma-Globulins - therapeutic use; Hematologic and hematopoietic diseases; Humans; Immunoglobulin G - metabolism; Medical sciences; Platelet Count; Platelet diseases and coagulopathies; Purpura, Thrombocytopenic - therapy; Human; Thrombocytopenia; Immunopathology; Immunoglobulins; Platelet; Intravenous administration; Immunotherapy; Autoimmune disease; Hemopathy; Essential
• ISSN: 0006-4971; 1528-0020
• DOI: 10.1182/blood.V73.3.662.662

Ten patients with idiopathic thrombocytopenic purpura (ITP) were studied before and following a rise in circulating platelets subsequent to infusions of intravenous gamma-globulin (400 mg /kg /day × 5 days). We quantitated the amount of circulating IgG capable of binding to normal donor platelets in vitro using an 125I-monoclonal anti-human IgG assay, as well as the amount of IgG associated with the patients’ platelets before and following therapy. We found no evidence for a decrease in platelet-specific IgG antibodies in these patients undergoing an acute response to therapy. These data suggest that the short-term efficacy of intravenous gammaglobulin is due to effects other than a substantive reduction in platelet reactive antibodies, such as the alteration of IgG-coated platelet destruction.